Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of Two Different Mixes of HMO-2FL + Humiome® Post LB Postbiotic (Postbiotic-LB) on Gastrointestinal Symptoms in Irritable Bowel Syndrome (IBS) Subjects

NCT06889779 is registered in ClinicalTrials.gov with dsm-firmenich Switzerland AG as lead sponsor.

NCT NCT06889779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06889779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of Two Different Mixes of HMO-2FL + Humiome® Post LB Postbiotic (Postbiotic-LB) on Gastrointestinal Symptoms in Irritable Bowel Syndrome (IBS) Subjects
Lead sponsor
dsm-firmenich Switzerland AG
Phase
Not applicable
Overall status
Completed
Start date
March 27, 2025
Completion date
June 6, 2026
Enrollment
353 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ibs (irritable bowel syndrome)